BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 236 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $2,182 | +44.2% | 353,133 | +18.6% | 0.07% | +23.7% |
| Q1 2024 | $1,513 | -25.0% | 297,822 | -11.6% | 0.06% | -27.2% |
| Q4 2023 | $2,017 | +37.6% | 336,765 | +62.6% | 0.08% | +17.4% |
| Q3 2023 | $1,466 | -28.6% | 207,095 | -29.0% | 0.07% | -22.5% |
| Q2 2023 | $2,053 | -5.7% | 291,556 | +11.7% | 0.09% | -13.6% |
| Q1 2023 | $2,177 | +20.1% | 260,986 | +65.2% | 0.10% | +3.0% |
| Q4 2022 | $1,813 | -99.9% | 157,944 | +62.6% | 0.10% | +35.1% |
| Q3 2022 | $1,224,000 | +48.4% | 97,127 | +24.5% | 0.07% | +19.4% |
| Q2 2022 | $825,000 | -25.5% | 77,988 | +14.5% | 0.06% | -15.1% |
| Q1 2022 | $1,108,000 | +298.6% | 68,114 | +239.6% | 0.07% | +108.6% |
| Q4 2021 | $278,000 | -3.5% | 20,056 | 0.0% | 0.04% | -7.9% |
| Q3 2021 | $288,000 | – | 20,056 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $40,692,000 | 16.07% |
| Fairmount Funds Management LLC | 3,343,107 | $35,370,000 | 8.10% |
| Kynam Capital Management, LP | 936,563 | $9,909,000 | 2.53% |
| Velan Capital Investment Management LP | 225,000 | $2,381,000 | 2.42% |
| ORACLE INVESTMENT MANAGEMENT INC | 603,994 | $6,390,000 | 1.94% |
| TANG CAPITAL MANAGEMENT LLC | 1,200,000 | $12,696,000 | 1.93% |
| MPM BioImpact LLC | 639,089 | $6,762,000 | 1.88% |
| Ghost Tree Capital, LLC | 325,000 | $3,439,000 | 1.79% |
| Sarissa Capital Management LP | 1,390,790 | $14,715,000 | 1.48% |
| Prosight Management, LP | 176,680 | $1,869,000 | 1.47% |